Published by Josh White on 19th April 2023
(Sharecast News) - Biotechnology company Renalytix announced the publication of new case studies in the Diabetic Nephropathy journal on Wednesday, highlighting the clinical value of 'KidneyIntelX' in risk stratification for the management of type-2 diabetes and chronic kidney disease (CKD).